1. Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Issue 1 (December 2017) Authors: Lin, Wei; Zhang, Panpan; Chen, Hua; Chen, Yu; Yang, Hongxian; Zheng, Wenjie; Zhang, Xuan; Zhang, Fengxiao; Zhang, Wen; Lipsky, Peter Journal: Arthritis research & therapy Issue: Volume 19:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Issue 5 (1st April 2020) Authors: van Vollenhoven, Ronald F.; Hahn, Bevra H.; Tsokos, George C.; Lipsky, Peter; Fei, Kaiyin; Gordon, Robert M.; Gregan, Irene; Lo, Kim Hung; Chevrier, Marc; Rose, Shawn Journal: Arthritis & rheumatology Issue: Volume 72:Issue 5(2020) Page Start: 761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. O9 Reduction of interferon-γ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE. (23rd March 2020) Authors: Seridi, Loqmane; Cesaroni, Matteo; Loza, Matt; Schreiter, Jessica; Sweet, Kristen; Campbell, Kim; Lipsky, Peter; Vollenhoven, Ronald van; Hahn, Bevra H; Tsokos, George C; Chevrier, Marc; Rose, Shawn; Baribaud, Frédéric; Jordan, Jarrat Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 1 Page Start: A12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. (April 2019) Authors: Jordan, Jarrat; Sweet, Kristen; Cesaroni, Matteo; Ma, Keying; Franks, Carol; Seridi, Loqmane; Schreiter, Jessica; Gordon, Robert; Lipsky, Peter; Vollenhoven, Ronald van; Tsokos, George C; Hahn, Bevra H; Rose, Shawn; Baribaud, Frédéric; Loza, Matthew J; Campbell, Kim Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 74 RNA-sequencing to dissect the role of selective HDAC6 inhibition on B cell signaling and germinal formation in lupus nephritis. (April 2019) Authors: Reilly, Christopher M; Ren, Jingjing; Grammer, Amrie; Lipsky, Peter Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 3 Polyunsaturated fatty acids (PUFAs) and specialized pro-resolving mediators (SPMs) are decreased in plasma and serum from SLE patients compared to healthy controls. (April 2019) Authors: Davis-Porada, Julia; Serhan, Charles; Norris, Paul; Lipsky, Peter; Salmon, Jane Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. GG-09 Comparative analysis of gene expression in lupus-affected tissues reveals common and disparate pathways of inflammation. (31st August 2016) Authors: Grammer, Amrie; Heuer, Sarah; Robl, Robert; Bachali, Prathyusha; Madamanchi, Sushma; Kretzler, Matthias; Berthier, Celine; Chong, Benjamin; Davis, Laurie; Lauwerys, Bernard; Catalina, Micelle; Lipsky, Peter Journal: Lupus science & medicine Issue: Volume 3(2016)Supplement 1 Page Start: A31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0435 MANAGEMENT OF ADVANCED GOUT: A CLAIMS-BASED ANALYSIS FROM THE UNITED STATES. (June 2019) Authors: Lawrence Edwards, N.; Schlesinger, Naomi; Clark, Sanders; Arndt, Theresa; Lipsky, Peter Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0279 POLYUNSATURATED FATTY ACIDS (PUFAS) AND SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS) ARE DECREASED IN PLASMA AND SERUM FROM SLE PATIENTS COMPARED TO HEALTHY CONTROLS. (June 2019) Authors: Davis-Porada, Julia; Serhan, Charles; Norris, Paul; Lipsky, Peter; Salmon, Jane E. Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OP0278 BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019) Authors: Cesaroni, Matteo; Seridi, Loqmane; Jordan, Jarrat; Sweet, Kristen; Keying, MA; Franks, Carol; Schreiter, Jessica; Lipsky, Peter; Vollenhoven, Ronald van; Hahn, Bevra H.; Rose, Shawn; Baribaud, Frederic; Loza, Matthew J; Campbell, Kim; Tsokos, George Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗